April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Intravitreous Bevacizumab and Standard Metabolic Control for Diabetic Macular Edema - A Contrast Sensitivity Pilot Study.
Author Affiliations & Notes
  • Augusto Motta
    Ophtalmology ( Retina and Vitreous), University of Sao Paulo, São Paulo, Brazil
  • Lisa Vasquez
    Ophtalmology ( Retina and Vitreous), University of Sao Paulo, São Paulo, Brazil
  • Daniel Araujo Ferraz
    Ophtalmology ( Retina and Vitreous), University of Sao Paulo, São Paulo, Brazil
  • Marcia S Queiroz
    Ophtalmology ( Retina and Vitreous), University of Sao Paulo, São Paulo, Brazil
  • Maria Teresa BC Bonanomi
    Ophtalmology ( Retina and Vitreous), University of Sao Paulo, São Paulo, Brazil
  • Walter Y Takahashi
    Ophtalmology ( Retina and Vitreous), University of Sao Paulo, São Paulo, Brazil
  • Footnotes
    Commercial Relationships Augusto Motta, None; Lisa Vasquez, None; Daniel Ferraz, None; Marcia Queiroz, None; Maria Teresa Bonanomi, None; Walter Takahashi, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 1762. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Augusto Motta, Lisa Vasquez, Daniel Araujo Ferraz, Marcia S Queiroz, Maria Teresa BC Bonanomi, Walter Y Takahashi; Intravitreous Bevacizumab and Standard Metabolic Control for Diabetic Macular Edema - A Contrast Sensitivity Pilot Study.. Invest. Ophthalmol. Vis. Sci. 2014;55(13):1762.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

To evaluate the effects on contrast sensitivity (CS) measuraments of intravitreal bevacizumab injections associated with standard metabolic control in eyes with diabetic macular edema.

 
Methods
 

Prospective, randomized, masked and interventional study. Forty-one eyes of 34 patients with type 2 DM, Glycate hemoglobin (HbA1c) less than 11% and previously treated macular edema three months before were randomized in two groups. The baseline examination consisted of visual acuity (VA), CS using the Pelli-Robson Charts, optical coherence tomography (OCT) and angiofluoresceinography for all eyes. Group 1 ( 21 eyes) was treated with intravitreal bevacizumab injection (1.25mg) at the weeks 0,6,12 and 18. Group 2 (20 eyes) received a sham injection at the weeks 0 and 6; and intravitreal bevacizumab injetion at the weeks 12 and 18. The Mann-Whitney U and Wilcoxon tests were applied to compare the differences between the two groups to categorical and continuous variables, respectively. The null hypothesis were rejected for P-value < 0.05.

 
Results
 

Reduction > 0.5% on average HbA1c levels in both groups in the period of 24 weeks. The corresponding data: the baseline was 8.28% ± 1.08 and 8.44% ± 1.20; and at week 24, 7.72% ± 0.99 and 7.66% ± 1.15 for groups 1 and 2 respectively. The mean CS for groups 1 and 2 was at baseline respectively: 1.14±0.37 and 1.00±0.32 logCS (p=0.36). At week 12, respectively 1.30±0.24 and 1.13±0.30 logCS (p=0.11). At week 24, respectively 1.28±0.23 and 1.21±0.22 logCS (p=0.51). No statistically significant difference was found between the two groups for VA, OCT or CS in the period of 6 months. Both groups improved substantially their VA, OCT and CS at week 12 and 24 (p<0.05).

 
Conclusions
 

The CS improvement demonstrated in both groups can be attributed to better control of the blood glucose with glycated hemoglobin (HbA1c) associated with intravitreal bevacizumab injections. Two consecutive intravitreal bevacizumab injections associated with standard metabolic control were comparable to two consecutive sham injections associated with standard metabolic control for macular structure and function in diabetic macular edema

     
Keywords: 499 diabetic retinopathy • 478 contrast sensitivity • 505 edema  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×